Lighthill Medical, Inc. is developing a family of catheters for the delivery of oncology agents for image-guided, minimally invasive interventional procedures. The Society of Interventional Radiology calls Interventional Oncology “the most rapidly changing domain of IR”. Over 700,000 individuals globally are diagnosed with liver cancer alone every year and 85 percent are non-resectable, which equates to 573,000 individuals who are potential candidates for targeted therapy. This represents a $340M market opportunity.